Products
Science
Autism
Company
Press & News

linkedin

Sign up for Early Access

Month: March 2021

March 16, 2021

Brain Scientific Announces Collaboration with JelikaLite in New Clinical Trial.

Learn More

Search for:

Recent Posts

We’re thrilled to share a significant achievement for JelikaLite. Our groundbreaking study, “Transcranial Photobiomodulation in Children Aged 2–6 Years: A Randomized Sham-Controlled Clinical Trial Assessing Safety, Efficacy, and Impact on Autism Spectrum Disorder Symptoms and Brain Electrophysiology,” has been published in Frontiers in Neurology 📚.
JelikaLite participated in Floreo VR’s inaugural virtual roundtable. A technology innovations such as Virtual Reality and wearables have begun to transform the delivery of behavioral therapy and developmental services for neurodiverse populations. Evidence demonstrates high levels of engagement among learners and the potential for improved outcomes. This panel discussed key trends, implications for therapy providers, what’s needed for further adoption, and the promise of these technologies.
JelikaLite is partnering with GoMo Health, for distribution of Cognilum treatment through national health care providers and Medicaid Managed Care Organizations throughout the U.S.. GoMo Health, a patient and consumer engagement company, works with providers, plans, employers, and pharma companies to improve engagement and patient outcomes across the world. GoMo Health has a growing Pediatric Autism program, making JelikaLite an ideal synergetic partner. On an annual basis, GoMo Health engages with over 8 million patients and members every day, focusing on serving economically disadvantaged communities worldwide.
In April 2023, JelikaLite together with SUNY Upstate Medical University, received a Jeff Lawrence Innovation Fund Manufacturing Grant of $50,000. The funds will be used by SUNY Upstate Medical University to conduct a new double-blind clinical trial using Cognilum treatment.
JelikaLite Announces Positive Results From a New Feasibility Study, Successful Raise of $760,000 and Acceptance into Mount Sinai Elementa Labs Program

Recent Comments

エロ人形 on JelikaLite has been granted Breakthrough Device Designation from the FDA for our Cognilum System – an individualized, non-invasive, investigational technology for the reduction of symptoms of moderate to severe autism spectrum disorder in pediatric patients.
ラブドール中古 on JelikaLite has been granted Breakthrough Device Designation from the FDA for our Cognilum System – an individualized, non-invasive, investigational technology for the reduction of symptoms of moderate to severe autism spectrum disorder in pediatric patients.
JackiMox on We are delighted to announce that JelikaLite has been chosen as one of 6 companies to present at the second annual Princeton Women Founders Startup Showcase on January 27, 2022
JackiMox on We are delighted to announce that JelikaLite has been chosen as one of 6 companies to present at the second annual Princeton Women Founders Startup Showcase on January 27, 2022
Amdbopich on JelikaLite’s StartEngine campaign is live! Since launching our campaign, our team has been blown away by the positive response we’ve received from our community. We are proud of our vision to revolutionalize the pediatric autism treatment and improve the lives of millions of families. We’re so excited to have you on this journey with us.

Archives

May 2024
November 2023
May 2023
February 2023
January 2023
April 2022
January 2022
December 2021
October 2021
August 2021
June 2021
March 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

Company

Products
Science
Autism
Company
Press & News

Rules

Disclaimer
Privacy Policy

Social

linkedin

Copyright ©2024 jelikalite. All rights reserved.